In a prospective study of 27 HD patients with SHPT and low 25-hydroxyvitamin D levels (below 20 ng/mL), Raquel Ojeda, MD, and colleagues at Hospital Universitario Reina Sofia in Córdoba, Spain, found that treatment with calcifediol (mean dose 266 mcg/week) for an average of three months resulted in a significant decrease in parathyroid hormone (PTH) levels (from 318 pg/mL prior to treatment to 229.6 pg/mL after treatment). All patients had normalization of 25-hydroxyvitamin D levels (above 30 ng/mL), which was associated with a significant a natural logarithm decrease in C-reactive protein, a marker of systemic inflammation, from 2.15 to 1.52, a significant rise in albumin levels from 3.2 to 3.4 g/dL, and a significant decrease in paricalcitol requirements (from 1.78 to 0.52 mcg/week).
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.